Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2639357 | 1.00 | HTT (0.57) | HTTCTSDPOLBCA2ANPEP | |
| SCHEMBL2639321 | 0.83 | — | — | |
| SCHEMBL2639319 | 0.83 | — | — | |
| SCHEMBL9006175 | 0.83 | — | — | |
| SCHEMBL9115562 | 0.79 | POLB (0.61) | HTTPOLBCA2ANPEP | |
| SCHEMBL9115555 | 0.79 | POLB (0.61) | HTTPOLBCA2ANPEP | |
| SCHEMBL30444229 | 0.78 | MME (0.57) | CTSD | |
| Hydrochloric Acid SCHEMBL8611963 | 0.77 | POLB (0.59) | HTTPOLBCA2ANPEP | |
| Hydrochloric Acid SCHEMBL8611957 | 0.77 | POLB (0.59) | HTTPOLBCA2ANPEP | |
| Hydrochloric Acid SCHEMBL8614479 | 0.77 | MMP3 (0.58) | HTTCTSDANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0836383-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | claimed |
| US-5504115-A | MERCAPTO-GROUP CONTAINING DIPEPTIDES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-04-02 | — | — | US | claimed |
| JP-H08500081-A | — | — | 1996-01-09 | — | — | JP | claimed |
| EP-0664789-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE. | — | 1995-09-06 | — | — | EP | claimed |
| EP-0664789-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | Merck & Co., Inc. (a New Jersey corp.) (US) | 1995-08-02 | — | — | EP | claimed |
| US-5352705-A | Dipeptide-based amide compounds; anticarcinogenic agents | MERCK & CO., INC. (US) | 1994-10-04 | — | — | US | claimed |
| WO-1994000419-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-01-06 | — | — | WO | claimed |
| WO-2006017369-A2 | USE OF A FARNESYL TRANSFERASE INHIBITOR IN THE TREATMENT OF VIRAL INFECTIONS | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | CAMPOCHIARO PETER A (US) | 2002-01-17 | — | — | US | disclosed |
| US-6160015-A | ADMINISTERING TO MAMMAL A FARNESYL PROTEIN TRANSFERASE INHIBITOR | UNIVERSITY OF CINCINNATI (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0840605-A4 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | UNIV CINCINNATI (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998057654-A1 | METHODS FOR TREATMENT OF OCULAR NEOVASCULARIZATION | JOHNS HOPKINS UNIVERSITY (US) | 1998-12-23 | — | — | WO | disclosed |
| EP-0840605-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEUROFIBROMATOSIS | University of Cincinnati (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997001275-A1 | COMBINATIONS OF INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5504115-A | MERCAPTO-GROUP CONTAINING DIPEPTIDES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0664789-A4 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE. | — | 1995-09-06 | — | — | EP | disclosed |
| EP-0664789-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | Merck & Co., Inc. (a New Jersey corp.) (US) | 1995-08-02 | — | — | EP | disclosed |
| US-5352705-A | Dipeptide-based amide compounds; anticarcinogenic agents | MERCK & CO., INC. (US) | 1994-10-04 | — | — | US | disclosed |
| WO-1994000419-A1 | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006967-A1 | METHODS OF TREATMENT OF OCULAR NEOVASCULARIZATION | GGT1, FNTA, PIGO | HTT 2104/4885CTSD 1024/4885POLB 1976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.